A phase I clinical trial (NCT00902044) testing HER2-CAR-T cells in osteosarcoma patients showed safety but only modest efficacy, with a lack of sustained responses linked to T cell exhaustion and antigen heterogeneity (65). Here, ERBB2 is linked to osteosarcoma.